Navigation Links
Atacama Labs Enters Into Partnership With Excella Gmbh, Which is Part of Fareva Holding, a Top 10 Global Contract Manufacturer
Date:3/4/2010

HELSINKI, Finland, March 4, 2010 /PRNewswire/ --

- A Finnish Company ATACAMA LABS OY and a German Based EXCELLA GmbH (Fareva Holding SA) Have Signed a Contract Manufacturing Agreement to Jointly Market and Sell PDG Granule and Tablet Manufacturing Services for the Pharmaceutical Industry

- Excella / Atacama Labs Offer for the Pharmaceutical Industry

Atacama Labs Oy has developed an innovative oral drug delivery technology (called 'pneumatic dry granulation' or 'PDG Technology(TM)'). The technology is aimed to replace existing solid dosage form development and manufacturing methods (like wet granulation or standard roller compaction) and will help both NCE galenic developers and life cycle managers to overcome development or differentiation issues.

The Excella / Atacama Labs partnership offers a cGMP compliant and FDA / EMEA / Anvisa certified environment to house Atacama's innovative and fully automated PDG equipment.

"We can develop almost any API (including difficult ones) into higher drug load tablets with good hardness and dissolution profiles and our clients can profit from new tablet characteristics to extend the life cycle of expiring drugs, which can mean several more years of protected sales of a blockbuster drug. In both cases, global economics can be hundreds of millions of additional revenue, naturally subject to magnitude of drug revenue," Mr. Mittwich, CEO of the Atacama Labs Oy concludes.

Fareva Holding SA : Manufacturing excellence

Excella GmbH is part of FAREVA Holding, one of the top 10 contract manufacturing organizations in the world. Fareva today is covering services in four fields - Pharmaceuticals, Cosmetics, Home Care & Industrial and Food.

FAREVA's Pharma Division provides a full service, ranging from pharmaceutical and chemical development, pilot scale manufacturing, supply of clinical studies till industrial-scale production, packaging and quality control. Ten pharmaceutical sites located throughout Europe serve the customer's needs for practically all marketed dosage forms as well as APIs.

Excella GmbH - located in Nuremberg, Germany - provides Contract Manufacturing Services, especially for the development, clinical supply and commercial manufacturing of solid dosage forms specially for cytotoxics, high potent or other critical actives with low occupational exposure levels.

"Atacama Lab's Pneumatic Dry Granulation or PDG Technology(TM) is revolutionary in the sense that it offers significant advantages in terms of API treatability, development speed and costs over today's dry and wet granulation processes " Dr. Michael Tschope , General Manager Pharma, Excella GmbH.

About Atacama Labs Oy

Atacama Labs Oy is a privately owned specialty pharmaceutical company that offers

    - galenic development from test granulations to full galenic development,
      and
    - contract manufacturing services from tablets to fully packaged
      products.


    The Company is located in Helsinki, Finland.
    http://www.atacamalabs.com

SOURCE Atacama Labs Oy

Back to top
'/>"/>
SOURCE Atacama Labs Oy
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Fibrocell Science, Inc. Enters Into Financing Agreement
2. US Fermenters Market to Reach $180 million by 2015, According to New Report by Global Industry Analysts, Inc.
3. Spectral diagnostics Raises $14 million and enters into strategic collaboration with BioMS Medical to commercialize treatment for sepsis
4. The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close
5. Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology
6. MRI & X-Ray Outsourcing Increasing From Hospitals and Imaging Centers Worldwide
7. iLife Americas, LLC Enters U.S. Wellness and Therapeutic Markets
8. China Biologic Products Enters into a Strategic Research and Development Agreement with IBT of CAMS
9. Childrens Hospital in Colorado Rounds off List of 24 Cord Blood Transplant Centers Worldwide Enrolling for ExCell Trial Studying StemEx(R) for Leukemia and Lymphoma
10. Pieris AG Enters into Anticalin Collaboration With Allergan, Inc.
11. Dr M Group Selects Health Robotics Technology Over RIVA for all of its I.V. Compounding Centers in South East Asia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... GA (PRWEB) , ... January 24, 2017 , ... ... and instrument solutions, announces the appointment of Steven F. McAllister as Executive Vice ... device experience in both the U.S. and international markets. Beginning his career at ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... upgrade its Nor-Tech cluster with user-friendly bootable Intel KNL. , Currently Cal ... integrated into Nor-Tech’s demo cluster. The demo cluster is a no-cost, no-strings opportunity ...
(Date:1/24/2017)... ... ... Oklahoma City based Sigma Blood Systems has established a relationship with Central ... product QC Manager 2.0. , Sigma Blood Systems CEO, Max Doleh, stated “We ... have decided to implement PERFEQTA and QC Manager 2.0, with PERFEQTA launching across multiple ...
(Date:1/24/2017)... YORK , Jan. 23, 2017  Today, the ... announce they have funded an important study that could ... prevent the onset of Alzheimer,s disease. This groundbreaking research ... Rockefeller University, led by Nobel Laureate Dr. Paul ... for Alzheimer,s disease. Fisher Center scientists have ...
Breaking Biology Technology:
(Date:1/3/2017)... 2017 Onitor, provider of digital health technology ... an innovative biometric data-driven program designed to aid weight ... the 2017 Consumer Electronics Show (CES) in ... U.S., the World Health Organization (WHO), have identified lifestyle ... who are overweight or obese. WHO also states that ...
(Date:12/19/2016)... España y TORONTO , 19 de diciembre de ... Biologics Inc. que permitirá el desarrollo acelerado de MSC-1, un anticuerpo ... varios tipos de tumor en 2017, con múltiples sitios previstos a ... ... con objetivo en el factor inhibidor de leucemia (LIF), una citoquina ...
(Date:12/15/2016)... , Dec. 15, 2016   WaferGen Bio-systems, Inc. ... genomics technology company, announced today that on December 13, ... Department of The Nasdaq Stock Market LLC which acknowledged ... price of WaferGen,s common stock had been at $1.00 ... has regained compliance with Listing Rule 5550(a)(2) of the ...
Breaking Biology News(10 mins):